林业发展局批准Zegfrovy,第一次口服治疗特定类型的非小细胞肺癌。 FDA approves Zegfrovy, first oral treatment for a specific type of non-small cell lung cancer.

林业发展局已核准Zegfrovy(sunvozertinib)为非小细胞肺癌患者首例定向口服治疗,EGFR Exon 20插入突变,这些突变在用白金化疗后有所进展。 The FDA has approved Zegfrovy (sunvozertinib) as the first targeted oral treatment for patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations who have progressed after platinum-based chemotherapy. 根据WU-KONG1B案的审判,Zegfrovy显示,总体答复率为46%,平均答复期为11.1个月。 Based on the WU-KONG1B trial, Zegfrovy showed a 46% overall response rate and a median response duration of 11.1 months. 林业发展局还批准了Oncomine Dx Express测试,作为检测NSCLC病人的这些突变的配套诊断。 The FDA also approved the Oncomine Dx Express Test as a companion diagnostic to detect these mutations in NSCLC patients.